BCOP study plan

Build a one-page decision template for each of the four steps of the pharmacotherapy process (design, implementation, monitoring, modification) and apply it to three solid-tumor regimens

Reconstruct from memory the indication, dosing basis (BSA, AUC, fixed), and dose-limiting toxicity for 15 high-yield cytotoxic regimens

Differentiate organ-dysfunction dose adjustments (renal, hepatic, obesity, older adult) for at least 12 agents and justify each adjustment in writing

Explain the pharmacology behind therapeutic drug monitoring for busulfan, methotrexate, and tacrolimus, including target ranges and sampling timing

Analyze drug-drug and drug-disease interactions across antineoplastics, anticonvulsants, azoles, and acid suppressants, and rank each by clinical severity

Construct monitoring plans (lab thresholds, timing, escalation triggers) for patients starting a targeted oral agent, an immune checkpoint inhibitor, and a bispecific T-cell engager

Distinguish infusion-related reactions from cytokine release syndrome and hypersensitivity by onset, phenotype, and first-line management

Sequence the modification steps for a regimen when a patient presents with grade 3 hematologic toxicity versus grade 3 non-hematologic toxicity

Classify and manage the acute toxicities of checkpoint inhibition by organ system, including steroid dosing tiers and tapering rules

Compare and contrast febrile neutropenia risk stratification and empiric antibiotic selection across high-risk, low-risk, and penicillin-allergic patients

Formulate antiemetic prophylaxis matching guideline-consistent triple or quadruple therapy to emetogenicity class and patient-specific risk factors

Design a tumor lysis syndrome prevention and treatment plan for high-, intermediate-, and low-risk patients, including rasburicase and allopurinol selection criteria

Evaluate and manage non-malignant hematology emergencies such as heparin-induced thrombocytopenia, thrombotic microangiopathy, and sickle cell vaso-occlusive crisis

Build a supportive care bundle for mucositis, diarrhea, and extravasation, specifying prevention, grading, and stepwise pharmacologic management

Assess and manage cancer-associated thrombosis, including anticoagulant selection in thrombocytopenia, brain metastases, and renal impairment

Design an opioid and non-opioid analgesic titration plan that addresses tolerance, opioid-induced constipation, and opioid-induced neurotoxicity

Integrate growth factor, transfusion, and iron-repletion thresholds into a coherent anemia and neutropenia supportive care algorithm

Differentiate palliative from hospice care and apply prognostic and goals-of-care communication frameworks to three patient scenarios

Select and titrate adjuvant psychotropics for depression, anxiety, and delirium in the oncology patient, accounting for drug interactions and organ function

Manage the final weeks of life pharmacologically, including opioid rotation, terminal agitation, and discontinuation of non-beneficial medications

Counsel survivors on late and long-term effects of anthracyclines, platinum agents, radiation, and HSCT, and map surveillance schedules to exposure

Formulate evidence-based recommendations for fertility preservation, sexual health, and bone health in cancer survivors

Distinguish palliative-intent from curative-intent supportive care endpoints and identify which outcomes trials use to measure benefit

Explain the structure, purpose, and regulatory basis of phase I through phase IV trials, including the role of the IRB and informed consent elements

Identify the drug-specific handling, monitoring, and documentation requirements that govern investigational agent dispensing and accountability

Evaluate clinical trial validity by appraising randomization, blinding, power, intention-to-treat analysis, and surrogate versus hard endpoints

Interpret survival statistics, hazard ratios, confidence intervals, and number needed to treat to translate a result into a clinical recommendation

Classify bias types and apply the appropriate tool to assess risk of bias in randomized and observational oncology studies

Map the drug development and approval pathway, including breakthrough designation, accelerated approval, and post-marketing requirements

Synthesize all four domains by completing two full-length timed mock examinations under test-day conditions

Diagnose and remediate the three weakest content areas identified by mock exam item analysis

Rehearse high-yield recall for toxicity management, dose adjustments, and key trial statistics in spaced-repetition format

Practice structured reasoning on unfamiliar scenarios so that defensible pharmacotherapy logic replaces rote recall